Explore

Sanofi expands Regeneron partnership with up to $8 billion deal in win for new CEO

Sanofi expands Regeneron partnership with up to $8 billion deal in win for new CEO

Oct 1 (Reuters) - Sanofi and US partner Regeneron on Thursday said they would expand their partnership to develop four new drugs, in a deal that includes up to $7 billion in milestone payments.

United Therapeutics Rises Following Federal Court Ruling on Patent Infringement

United Therapeutics Rises Following Federal Court Ruling on Patent Infringement

United Therapeutics Rises Following Federal Court Ruling on Patent Infringement

Popular dating platform Grindr makes surprising healthcare move

Popular dating platform Grindr makes surprising healthcare move

Grindr's CEO has an interesting take on what the company's future will look like.

Sanofi, Regeneron expand tie-up with $8 billion drug-development deal, settle legal dispute

Sanofi, Regeneron expand tie-up with $8 billion drug-development deal, settle legal dispute

By Bhanvi Satija and Mariam Sunny Oct 1 (Reuters) - Sanofi and Regeneron said on Thursday they will develop four new drugs together in a deal worth up to $8 billion and settle prior litigation, moves analysts said signal a reset of their strained partnership and an early win for the French

Novartis strikes up to $7.8 billion mRNA deal with China's Abogen

Novartis strikes up to $7.8 billion mRNA deal with China's Abogen

By Bhanvi Satija Oct 2 (Reuters) - Chinese biotech company Abogen said on Friday it has signed a licensing deal worth up to $7.8 billion with Novartis to develop messenger RNA-based therapy, underscoring the Swiss drugmaker's growing focus on an emerging class of treatments.

Sanofi to pay Regeneron up to $8 billion to add new antibodies under Dupixent partnership

Sanofi to pay Regeneron up to $8 billion to add new antibodies under Dupixent partnership

Oct 1 (Reuters) - Sanofi said on Thursday it would pay US partner Regeneron $1 billion upfront and up to $7 billion in milestone payments to bring four new antibodies under the partnership behind their blockbuster eczema drug Dupixent, which sent the French drugmaker's shares 2% higher in early

ProFound Therapeutics Seeks Senior Director for Alliance and Program Management to Advance Drug Discovery

ProFound Therapeutics Seeks Senior Director for Alliance and Program Management to Advance Drug Discovery

ProFound Therapeutics Seeks Senior Director for Alliance and Program Management to Advance Drug Discovery

Goldman Sachs Removes ConocoPhillips from 'Director's Cut' List Amid Portfolio Reassessment

Goldman Sachs Removes ConocoPhillips from 'Director's Cut' List Amid Portfolio Reassessment

Goldman Sachs Removes ConocoPhillips from 'Director's Cut' List Amid Portfolio Reassessment

Nextdoor to Transfer Stock Exchange Listing from NYSE to Nasdaq Capital Market

Nextdoor to Transfer Stock Exchange Listing from NYSE to Nasdaq Capital Market

Nextdoor to Transfer Stock Exchange Listing from NYSE to Nasdaq Capital Market

Is Nvidia a good long-term buy? Why its massive size may not matter

Is Nvidia a good long-term buy? Why its massive size may not matter

Prime Capital Financial’s Will McGough wants investors to look past NVDA’s market cap and focus on its earnings, valuation, and its role in the artificial intelligence buildout.

Exelixis Seeks Senior Financial Analyst for Corporate Finance, M, and Business Development

Exelixis Seeks Senior Financial Analyst for Corporate Finance, M, and Business Development

Exelixis Seeks Senior Financial Analyst for Corporate Finance, M, and Business Development

Citi delivers major verdict after Moderna’s remarkable 703% run

Citi delivers major verdict after Moderna’s remarkable 703% run

Moderna’s rally has priced in unrealistic expectations for its cancer drug sales.